Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 50

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 50
---
 effect on the ability of each of TELO and TELI to motivate or retain management personnel and other key employees. In addition, no assurance can be given that TELO will be able to attract, motivate or retain management personnel and other key employees to the same extent that TELI had previously been able. If management personnel or other key employees terminate their employment, TELO’s business activities may be adversely affected, and management’s attention may be diverted from successfully integrating TELO and TELI which may cause TELO’s progress to suffer.

TELO will incur significant transaction and integration-related costs in connection with the Merger, which could adversely affect TELO’s ability to execute its integration plan and achieve the anticipated benefits of the Merger.

TELO expects to incur a number of non-recurring costs associated with the Merger and combining the operations of the two companies. TELO continues to assess the magnitude of these Merger and integration-related costs, and additional unanticipated

costs may also be incurred. Although TELO expects that the elimination or avoidance of duplicative costs, as well as the realization of other efficiencies related to the integration of the businesses of TELO and TELI, should allow TELI to offset integration-related costs over time, this net benefit may not be achieved in the near term or at all.

The market price of TELO Common Stock may decline as a result of the Merger and the issuance of shares of TELO Common Stock to TELI stockholders in the Merger may have a negative impact on TELO’s financial results, including future earnings per share.

The market price of TELO Common Stock may decline as a result of the Merger, and holders of TELO Common Stock (including holders of TELI Common Stock who receive TELO Common Stock) could see a decrease in the value of their investment holdings if, among other things, TELO is unable to achieve the expected growth in earnings, or if the anticipated benefits, including synergies, cost savings, innovation and operational efficiencies, from the Merger are not realized, or if the Merger and integration-related costs related to the Merger are greater than expected. The market price of TELO Common Stock may also decline if TELO does not achieve the anticipated benefits of the Merger as rapidly or to the extent expected by financial or industry analysts or if the effects of the Merger on TELO’s financial position, results of operations or cash flows are not otherwise consistent with the expectations of financial or industry analysts. The issuance of